Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration

Haider J Warraich; Bray Patrick-Lake; Anindita Saha; Leeda Rashid; Vinay Pai; Ali Abbasi; Matthew C Diamond; Troy Tazbaz; Robert M Califf

doi:10.1016/j.jacc.2024.10.075

Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration

J Am Coll Cardiol. 2024 Nov 19:S0735-1097(24)10028-9. doi: 10.1016/j.jacc.2024.10.075. Online ahead of print.

Authors

Haider J Warraich¹, Bray Patrick-Lake², Anindita Saha², Leeda Rashid², Vinay Pai², Ali Abbasi², Matthew C Diamond², Troy Tazbaz², Robert M Califf²

Affiliations

¹ U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Electronic address: haider.warraich@fda.hhs.gov.
² U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

PMID: 39641737
DOI: 10.1016/j.jacc.2024.10.075

No abstract available

Keywords: U.S. Food and Drug Administration; artificial intelligence; cardiovascular disease; continuous glucose monitors; diabetes mellitus; digital health technologies; large language models.